Weiwei Chen Selected Research

quinoline-val-asp(OMe)-CH2-OPH

3/2022	Nrf2 protects against cerebral ischemia-reperfusion injury by suppressing programmed necrosis and inflammatory signaling pathways.
6/2018	NLRP3 Inflammasome Is Involved in Q-VD-OPH Induced Necroptosis Following Cerebral Ischemia-Reperfusion Injury.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Weiwei Chen Research Topics

Disease

44	Neoplasms (Cancer) 08/2022 - 02/2002
14	Pancreatitis 03/2022 - 01/2017
13	Neoplasm Metastasis (Metastasis) 06/2022 - 09/2012
13	Inflammation (Inflammations) 01/2022 - 01/2015
10	Lung Neoplasms (Lung Cancer) 01/2022 - 02/2002
9	Breast Neoplasms (Breast Cancer) 10/2019 - 04/2008
8	Infections 01/2020 - 11/2008
6	Sepsis (Septicemia) 10/2022 - 01/2017
6	Lupus Nephritis 03/2021 - 01/2014
6	Asthma (Bronchial Asthma) 02/2020 - 05/2013
5	Heart Failure 01/2022 - 01/2015
5	Myocardial Infarction 06/2021 - 01/2019
5	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2021 - 01/2017
5	Autoimmune Diseases (Autoimmune Disease) 01/2020 - 03/2018
5	Systemic Lupus Erythematosus (Libman-Sacks Disease) 04/2019 - 12/2014
4	Atopic Dermatitis (Atopic Eczema) 12/2022 - 01/2021
4	Brain Ischemia (Cerebral Ischemia) 03/2022 - 07/2013
4	Acute Necrotizing Pancreatitis 01/2022 - 11/2019
4	Psoriasis (Pustulosis Palmaris et Plantaris) 01/2022 - 01/2019
4	Cardiovascular Diseases (Cardiovascular Disease) 01/2022 - 01/2017
4	Pain (Aches) 08/2021 - 01/2019
4	Carcinogenesis 12/2020 - 02/2002
4	Reperfusion Injury 10/2020 - 07/2013
4	Necrosis 11/2019 - 01/2018
3	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 03/2022 - 01/2018
3	COVID-19 01/2022 - 06/2021
3	Myopia 01/2022 - 06/2020
3	Nasopharyngeal Neoplasms (Cancer of the Nasopharynx) 05/2021 - 04/2014
3	Carcinoma (Carcinomatosis) 01/2021 - 01/2013
3	Acute Kidney Injury (Acute Renal Failure) 01/2021 - 01/2015
3	Hemorrhage 01/2020 - 02/2014
3	Chronic Obstructive Pulmonary Disease (COPD) 04/2019 - 01/2018
3	Atherosclerosis 03/2019 - 01/2018
3	Triple Negative Breast Neoplasms 12/2018 - 01/2018
3	Glaucoma 08/2018 - 01/2014
2	Neuroinflammatory Diseases 03/2022 - 01/2021
2	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 01/2022 - 06/2012
2	Ventricular Remodeling 01/2022 - 01/2019
2	Hepatocellular Carcinoma (Hepatoma) 01/2022 - 01/2017
2	Rectal Neoplasms (Rectal Cancer) 01/2022 - 11/2021
2	Nasopharyngeal Carcinoma 01/2022 - 06/2013
2	Hypertension (High Blood Pressure) 10/2021 - 02/2014
2	Coronary Artery Disease (Coronary Atherosclerosis) 06/2021 - 01/2021
2	Vitiligo 01/2021 - 01/2021
2	Mitochondrial Diseases (Mitochondrial Disease) 01/2021 - 01/2017

Drug/Important Bio-Agent (IBA)

21	Proteins (Proteins, Gene)FDA Link 01/2022 - 11/2009
12	Long Noncoding RNAIBA 05/2022 - 01/2018
10	Biomarkers (Surrogate Marker)IBA 01/2022 - 01/2017
10	MicroRNAs (MicroRNA)IBA 01/2022 - 01/2018
10	Pharmaceutical PreparationsIBA 01/2022 - 01/2014
8	Messenger RNA (mRNA)IBA 10/2021 - 03/2006
8	CytokinesIBA 08/2021 - 01/2018
7	Therapeutic UsesIBA 10/2021 - 01/2014
7	Biological ProductsIBA 01/2019 - 01/2015
4	Indicators and Reagents (Reagents)IBA 12/2022 - 09/2017
4	InflammasomesIBA 03/2022 - 06/2018
4	Mydriatics (Cycloplegics)IBA 01/2022 - 06/2020
4	Peptides (Polypeptides)IBA 12/2021 - 09/2015
4	hydroxide ionIBA 01/2021 - 01/2018
4	VaccinesIBA 10/2020 - 11/2008
3	6-methyladenineIBA 06/2022 - 06/2018
3	CeruletideIBA 01/2022 - 10/2018
3	Opioid Analgesics (Opioids)IBA 01/2022 - 01/2019
3	LigandsIBA 01/2022 - 06/2011
3	Interleukin-6 (Interleukin 6)IBA 01/2022 - 12/2015
3	Plasminogen Activator Inhibitor 1IBA 01/2022 - 01/2018
3	LipopolysaccharidesIBA 10/2021 - 10/2019
3	Anti-Bacterial Agents (Antibiotics)IBA 07/2021 - 01/2017
3	Immunoglobulin G (IgG)IBA 07/2021 - 01/2017
3	Taurocholic Acid (Sodium Taurocholate)IBA 01/2021 - 10/2018
3	Small Interfering RNA (siRNA)IBA 10/2020 - 12/2017
3	Immunosuppressive Agents (Immunosuppressants)IBA 01/2020 - 01/2017
3	AntioxidantsIBA 01/2019 - 01/2015
3	Retinaldehyde (Retinal)IBA 01/2018 - 01/2014
2	quinoline-val-asp(OMe)-CH2-OPHIBA 03/2022 - 06/2018
2	Transcription Factors (Transcription Factor)IBA 01/2022 - 01/2020
2	HLA-DQB1 antigen (HLA DQB1)IBA 01/2022 - 01/2021
2	Atrial Natriuretic Factor (ANF)IBA 01/2022 - 01/2020
2	nilotinib FDA Link 01/2022 - 06/2012
2	HLA-DR Antigens (HLA-DR)IBA 01/2022 - 01/2020
2	Trace Elements (Biometals)IBA 11/2021 - 10/2017
2	Antihypertensive Agents (Antihypertensives)IBA 10/2021 - 02/2014
2	Transient Receptor Potential ChannelsIBA 08/2021 - 01/2021
2	Genetic Markers (Genetic Marker)IBA 01/2021 - 01/2020
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2021 - 10/2020
2	1-phenyl-3,3-dimethyltriazene (PDT)IBA 01/2021 - 11/2020
2	Interleukin-17 (Interleukin 17)IBA 01/2021 - 01/2021
2	Matrix Metalloproteinases (MMPs)IBA 01/2021 - 01/2017
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2021 - 06/2011
2	Cisplatin (Platino)FDA LinkGeneric 01/2021 - 01/2018
2	Arginine (L-Arginine)FDA Link 01/2021 - 01/2020

Therapy/Procedure

25	Therapeutics 10/2021 - 04/2012
8	Radiotherapy 01/2022 - 07/2018
6	Drug Therapy (Chemotherapy) 08/2021 - 01/2017
5	Ligation 10/2022 - 10/2019
5	Punctures 10/2022 - 10/2019
5	Transplantation 01/2020 - 01/2014
2	Immunotherapy 01/2022 - 11/2008
2	Chinese Traditional Medicine (Traditional Chinese Medicine) 11/2021 - 10/2021
2	Photochemotherapy (Photodynamic Therapy) 01/2021 - 11/2020